Cerebras Systems' stock has fallen 46.5% since its IPO, hitting a post-IPO low amid missed revenue targets and margin pressure. Despite this, UBS set a bullish price target of $330, implying nearly 100% upside, citing strong demand for its AI chips and significant multi-year contracts, including a $20B deal with OpenAI. The company expects core revenue to nearly triple by 2027, supported by a $25.4 billion backlog and upcoming product launches. Risks remain due to heavy reliance on OpenAI, but analysts see the current stock price as undervalued compared to its growth potential.
Cerebras Systems (CBRS) is trading at USD 174.05 on Pluang as of Oct 05, 2026 18:33 WIB, up 4.58% for the day but still well below its 52-week high of USD 311.07. This price sits just above its 52-week low of USD 166.43, highlighting the stock's significant volatility since its IPO. With a market cap of $39.54 billion, CBRS remains a notable player in the technology sector despite its recent price fluctuations and ongoing operational challenges.
Cerebras Systems' stock has fallen about 50% since its May IPO, hitting its lowest price as it lost a major inference workload contract for OpenAI's GPT-6.1 Sol AI model to Nvidia. This setback, combined with insider selling following the expiration ...
Cerebras Systems' stock dropped below its IPO price on September 30, 2026, coinciding with the end of its post-IPO lockup period and insider filings to sell shares worth over $84 million. The decline was also fueled by reports questioning whether Ope...
